Dengue Fever News and Research

RSS

Dengue fever is a mosquito-borne tropical disease caused by the dengue virus. Symptoms typically begin three to fourteen days after infection. These may include a high fever, headache, vomiting, muscle and joint pains, and a characteristic skin rash.

Also in Global Health News: GM mosquitoes; Iodine deficiency in Nepal; South African health workers strike; Novartis to build vaccine plant in Brazil; Population control in Niger

Malaysia is still "considering releasing" up to 3,000 mosquitoes that are genetically modified to "combat dengue fever, in a landmark field trial that has come in for criticism from environmentalists," Agence France-Presse reports. The insects are modified "so that their offspring quickly die," which researchers hope will cull the population and lessen the risk of dengue.

30 Aug 2010

Tamir Biotechnology's three compounds effective show potential for yellow fever

Tamir Biotechnology, Inc.(formerly Alfacell Corporation) announced today that scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID) confirmed that testing of three of our company's compounds showed in vitro results rarely seen before by the U.S. government for yellow fever.

11 Aug 2010

U.S. Senators introduce legislation to encourage R&D aimed at neglected pediatric diseases

"New bipartisan legislation was introduced in the U.S. Senate last week which seeks to encourage innovative [research and development] R&D by drugmakers aimed at treating rare and neglected pediatric diseases," PharmaTimes reports.

11 Aug 2010

NIAID launches clinical trials of dengue vaccine

After more than a decade of development, the National Institute of Allergy and Infectious Diseases (NIAID) has started clinical trials to test a vaccine to protect against the dengue virus, a product researchers hope may one day "help prevent a disease to which 2.5 billion people are exposed," CIDRAP News reports (Roos, 8/9).

11 Aug 2010

NIH begins human clinical testing for dengue virus vaccine

After more than a decade of development at the National Institutes of Health, a vaccine to prevent infection by the mosquito-borne dengue virus has begun human clinical testing. The vaccine was developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and is undergoing clinical study at the Johns Hopkins Bloomberg School of Public Health in Baltimore.

10 Aug 2010

Need for shelter in Haiti; Avoiding disease outbreaks; Presidential election

USAID Director Rajiv Shah "says shelter and rubble removal are immediate priorities in the reconstruction efforts in earthquake-devastated Haiti," VOA News reports. Shah briefed the House Foreign Relations Subcommittee on the Western Hemisphere Thursday, and also "said between 300,000 and 400,000 units of shelter are needed. He said aid workers are trying to provide about 135,000 transitional structures right now."

31 Jul 2010

Dengue fever emerges as major health threat in Gulf coast cities

Several cases of dengue fever, a potentially fatal viral disease transmitted by the bite of urban dwelling Aedes aegypti and Aedes albopictus mosquitoes, have recently been reported in the continental United States. Prevalent in Central America and the Caribbean, dengue fever's most common symptoms include fever, chills, headache, and body aches lasting several days. The disease's more threatening form, dengue hemorrhagic fever, can cause internal bleeding, loss of blood pressure, and death. Over the past five years, outbreaks of both forms of the disease have been reported in Texas and Florida.

28 Jul 2010

NIH awards MacroGenics $9.8 million grant for three projects

MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants representing total funding of $9.8 million.

15 Jul 2010

IBM dedicates $100 million for global initiative to improve healthcare quality and costs

IBM today announced plans to enlist some of the company's leading scientists and technologists to help medical practitioners and insurance companies provide high-quality, evidence-based care to patients. As part of this initiative, IBM is collaborating with clinicians in medical institutions and hiring medical doctors to work alongside its researchers to develop new technologies, scientific advancements and business processes for healthcare and insurance providers.

15 Jul 2010

IBM and Peking University People's Hospital build evidence-based patient centric care system

IBM and Peking University People's Hospital have built an evidence-based patient centric care (ePC3) system to enable cooperation and resource sharing among medical services providers for improved patient care.

15 Jul 2010

Bacteria that will kill Dengue bearing mosquitoes on the way

Dengue is a deadly viral fever spread by mosquito bites that kills thousands around the world each year. Now researchers from James Cook University and University of Queensland are working on a bacterium called Wolbachia that can stop the spread of this virus.

6 Jul 2010

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant protection in the initial animal survival studies of Dengue virus infection. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

21 Jun 2010

Help Conquer Cancer Project taps World Community Grid to discover structure of cancer-related proteins

Scientists have devised a way to automate and accelerate a manual, complex process that enables researchers to more easily discover the structure of cancer-related proteins, and, eventually, formulate cancer cures. This new, automated approach may also help the exploration of other diseases and food-related research.

15 Jun 2010

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

Roughly half the world's population still lives in areas at risk of malaria transmission. Even in the United States, 1500 cases of malaria are reported annually on average.

15 Jun 2010

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

NanoViricides, Inc. reports that its anti-Dengue drug candidates demonstrated significant efficacy in the recently completed preliminary cell culture studies. The studies were performed in the laboratory of Dr. Eva Harris, Professor of Infectious Diseases at the University of California, Berkeley.

2 Jun 2010

HZI researchers develop new method to produce insulin for treatment of diabetes

More than eight million diabetics live in Germany. Diabetes is not restricted to our prosperous society and the highest growth rates often occur in countries with aspiring economies such as in Asia. Worldwide, more than 285 million people suffer from this illness; with 50 million diabetics, India is the country with the most people affected by this disease.

27 May 2010

NanoViricides reports $2.95M in cash, $305,000 in prepaid expenses for quarter ended March 31, 2010

NanoViricides, Inc., has filed its quarterly report with the Securities and Exchange Commission on Thursday, May 20th, in a timely fashion.

24 May 2010

Saint Louis University conducts research to find safe, effective vaccination for dengue

Sponsored by the National Institutes of Health, Saint Louis University's Center for Vaccine Development is conducting research of an investigational vaccine designed to prevent people from contracting dengue, a potentially lethal virus that has rapidly spread around the world.

20 May 2010

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Inviragen has announced the initiation of the first clinical trial of its vaccine to protect against dengue fever. The trial, to be conducted at Saint Louis University, is designed to assess the safety of Inviragen's investigational dengue vaccine.

20 May 2010

Novartis employees organise events to contribute to community organizations

In a spring tradition that has become well entrenched at the company over the past 14 years, employees of Novartis from across Canada are today joining their colleagues around the world in taking time away from their work to contribute to community organizations.

15 May 2010

Dengue Fever News and Research

Further Reading

Also in Global Health News: GM mosquitoes; Iodine deficiency in Nepal; South African health workers strike; Novartis to build vaccine plant in Brazil; Population control in Niger

Tamir Biotechnology's three compounds effective show potential for yellow fever

U.S. Senators introduce legislation to encourage R&D aimed at neglected pediatric diseases

NIAID launches clinical trials of dengue vaccine

NIH begins human clinical testing for dengue virus vaccine

Need for shelter in Haiti; Avoiding disease outbreaks; Presidential election

Dengue fever emerges as major health threat in Gulf coast cities

NIH awards MacroGenics $9.8 million grant for three projects

IBM dedicates $100 million for global initiative to improve healthcare quality and costs

IBM and Peking University People's Hospital build evidence-based patient centric care system

Bacteria that will kill Dengue bearing mosquitoes on the way

NanoViricides' anti-Dengue drug candidates demonstrate potential against severe virus infection

Help Conquer Cancer Project taps World Community Grid to discover structure of cancer-related proteins

Entomologists to develop genetically engineered bacteria for killing mosquito larvae

Anti-Dengue drug candidates demonstrate efficacy in preliminary cell culture studies

HZI researchers develop new method to produce insulin for treatment of diabetes

NanoViricides reports $2.95M in cash, $305,000 in prepaid expenses for quarter ended March 31, 2010

Saint Louis University conducts research to find safe, effective vaccination for dengue

Inviragen initiates first clinical trial of DENVax vaccine to protect against dengue fever

Novartis employees organise events to contribute to community organizations

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News